Novartis to License Google "Smart Lens" Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis to License Google "Smart Lens" Technology



Novartis’ eye care division, Alcon, has entered into an agreement with a division of Google to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a specialized team within Google, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to further enhance Alcon's pipeline. The transaction remains subject to anti-trust approvals.

Under the agreement, Google[x] and Alcon will collaborate to develop a "smart lens" that has the potential to address ocular conditions. The smart lens technology involves non-invasive sensors, microchips, and other miniaturized electronics, which are embedded within contact lenses.

Novartis' interest in this technology is currently focused in two areas. One, helping diabetic patients manage their disease by providing a continuous, minimally invasive measurement of the body's glucose levels via a "smart contact lens" which is designed to measure tear fluid in the eye and connects wirelessly with a mobile device; and two, for people living with presbyopia who can no longer read without glasses, the "smart lens" has the potential to provide accommodative vision correction to help restore the eye's natural autofocus on near objects in the form of an accommodative contact lens or intraocular lens as part of the refractive cataract treatment.

Source: Novartis

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here